An innovative 3-gene blood test suitable for large-scale screening of pregnancy complications

Around 134 million babies are born every year. Of these, 1 in 5 pregnancies ends in a complication that threatens the lifelong health of both mother and baby. PregnaSense aims to develop simpler, more sensitive and cost-effective tests to predict pregnancy complications early and accurately enough for effective prevention. Existing or competing predictive methods require sophisticated equipment or have limited sensitivity. Our company has filed and will file patents on core technology for the prediction of pregnancy complications based on simple equipment and sensitive biomarkers, namely circulating RNA markers. Our easy-to-use method is strategically positioned for widespread adoption in the multi-billion dollar market for early prediction of pregnancy complications.